# U.S. Food and Drug Administration Type: organization (FDA) Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/us-food-and-drug-administration-organization Canonical HTML page: https://getbiobrief.com/entity/us-food-and-drug-administration-organization ## Timeline - **2027-01-01**: Target Commercialization — Anticipated EU launch for iopofosine I 131 treatment of WM. - **2026-09-30**: EMA Submission — Target window for filing the CMA for iopofosine I 131 in the European Union. - **2026-06-30**: CLR 125 Data Readout — Expected early data from the Phase 1b study in Triple Negative Breast Cancer. - **2026-04-14**: JPM Earnings — JPMorgan Chase reports Q1 results amid regulatory and legal headwinds. - **2026-04-10**: FDA Decision Date — Expected regulatory ruling on orforglipron oral weight loss drug. - **2026-03-24**: Phase III Initiation — First patient dosed at Peking Union Medical College Hospital in China. - **2026-03-04**: Annual Results Announcement — CEO James Caruso provides corporate updates and confirms regulatory timelines. - **2026-01**: Regulatory Designations — HMI-115 receives FDA Fast Track and NMPA Breakthrough Therapy designations. - **2026**: Trial Expansion — Continued enrollment across global multicenter sites for the 24-week study. - **2025-12-31**: Fiscal Year End — Cellectar concludes a year focused on pipeline execution and supply chain strengthening. - **2025-Q4**: Phase II Completion — Global multicenter Phase II trial results published in The Lancet showing efficacy and safety. - **2023**: Zepbound Approval — FDA expands tirzepatide approval to include chronic weight management. - **2022**: Mounjaro Launch — Tirzepatide enters the market for Type 2 Diabetes treatment. ## Recent coverage (7 stories) ### First Nicotine Pouch MRTP: How ZYN’s 10 Flavors Achieved FDA Reduced‑Exposure Status 2026-07-04 09:17:08 · Sentiment: Bullish · Impact: 7/10 · Sources: 2 Philip Morris’s ZYN secured the first FDA modified risk orders for a nicotine pouch, authorizing reduced‑exposure marketing for 10 flavors. The decision sets a regulatory benchmark for oral nicotine products. Full story: https://getbiobrief.com/story/fda-mrtp-zyn-biopharma-10-flavors ### Hope Medicine Doses First Patient in Phase III Trial for Endometriosis Therapy 2026-03-25 12:13:15 · Sentiment: Bullish · Impact: 7/10 · Sources: 10 Hope Medicine Inc. has initiated dosing in its Phase III clinical trial for HMI-115, a first-in-class non-hormonal monoclonal antibody for endometriosis. This milestone marks the first time a non-hormonal treatment for this condition has reached Phase III development globally, offering a potential alternative to traditional hormonal therapies. Full story: https://getbiobrief.com/story/hope-medicine-hmi-115-phase-iii-endometriosis ### Eli Lilly Faces Critical April 10 FDA Decision on Oral Weight Loss Candidate 2026-03-23 00:14:59 · Sentiment: Bullish · Impact: 7/10 · Sources: 5 Eli Lilly (LLY) is approaching a pivotal April 10 regulatory milestone for orforglipron, its experimental oral GLP-1 receptor agonist, as it seeks to expand its $11 billion weight-loss portfolio. While the broader market faces volatility from the banking sector's upcoming earnings on April 14, the biotech industry is laser-focused on the potential shift from injectable to oral metabolic therapies. Full story: https://getbiobrief.com/story/eli-lilly-orforglipron-fda-decision-april-catalyst ### Texas Governor Orders Probe into Chinese Medical Device Supply Chain Risks 2026-03-11 11:18:52 · Sentiment: Bearish · Impact: 6/10 · Sources: 2 Texas Governor Greg Abbott has launched a formal investigation into the safety and security of medical devices manufactured in China and used within the state's healthcare system. The move signals a growing trend of state-level scrutiny over international medical supply chains and potential vulnerabilities in critical healthcare infrastructure. Full story: https://getbiobrief.com/story/texas-governor-investigation-china-medical-devices ### Cellectar Biosciences Targets 2027 EU Launch for Iopofosine I 131 2026-03-05 01:14:41 · Sentiment: Bullish · Impact: 7/10 · Sources: 2 Cellectar Biosciences has confirmed its trajectory for a Q3 2026 regulatory submission to the EMA for its lead radiotherapeutic, iopofosine I 131. The company is simultaneously advancing its Phase 1b study of CLR 125 in triple-negative breast cancer, marking a significant expansion of its phospholipid drug conjugate platform. Full story: https://getbiobrief.com/story/cellectar-biosciences-2025-results-iopofosine-update ### FDA to Incentivize Speed: New Bonus Program for Accelerated Drug Reviews 2026-02-26 23:39:50 · Sentiment: Bullish · Impact: 7/10 · Sources: 5 The U.S. Food and Drug Administration is introducing a landmark performance-based bonus system for staff members who complete drug application reviews ahead of schedule. This shift toward private-sector incentive models aims to clear regulatory backlogs and accelerate patient access to new therapies. Full story: https://getbiobrief.com/story/fda-bonus-payments-speedy-drug-reviews ### FDA to End Two-Study Mandate for New Drugs to Accelerate Market Access 2026-02-18 23:53:34 · Sentiment: Bullish · Impact: 7/10 · Sources: 3 The U.S. Food and Drug Administration is moving to eliminate the long-standing requirement for two pivotal clinical trials for new drug approvals. This regulatory shift aims to significantly reduce the time and cost of drug development, prioritizing faster patient access to innovative therapies. Full story: https://getbiobrief.com/story/fda-drops-two-study-requirement-drug-approvals --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.